The U.S. Remote Patient Monitoring Market was valued at USD 9.4 billion in 2024 and is estimated to grow at a CAGR of 10.6% to reach USD 25.2 billion by 2034.
The steady rise is linked to several influential factors, including the growing rate of long-term health conditions across the country and expanding reimbursement frameworks that encourage digital care adoption. RPM technologies allow individuals to measure essential health indicators such as blood glucose levels, heart rate, and blood pressure from their homes, supporting earlier intervention and minimizing unnecessary hospital visits. As chronic disease cases continue to climb, these platforms are becoming an essential component of modern care models, particularly for long-term disease control and preventive healthcare. The RPM landscape covers a wide spectrum of medical tools designed to capture and transfer patient information outside clinical facilities. It incorporates digital systems that evaluate incoming data and support ongoing communication between patients and healthcare professionals. In addition, the market includes specialized devices engineered by manufacturers to integrate efficiently with dedicated RPM platforms, improving data synchronization and overall care delivery.
The cardiac monitoring devices segment held a 19.6% share in 2024. Its expansion is attributed to the substantial burden of cardiovascular conditions nationwide and a rising need for continuous, real-time cardiac oversight that enables quicker diagnosis and more effective treatment. Advancements in cardiac-focused RPM technologies have elevated accuracy through refined sensors and intelligent analytics capable of assessing heart rhythm patterns, variability, and additional vital indicators with precision.
The diabetes segment accounted for a 56.4% share in 2024, supported by the increasing number of individuals managing diabetes and the growing demand for consistent, real-time metabolic monitoring. While the condition remains most common among adults above 45, diagnoses among younger groups are becoming more frequent, increasing the need for reliable digital tools that simplify ongoing disease management. RPM solutions play a meaningful role in monitoring blood glucose and other metabolic markers and have significantly improved the way diabetes is managed through enhanced technical capabilities.
The home-care settings segment held 69.8% share in 2024, driven by rising interest in decentralized care models and a preference for managing personal health from familiar surroundings. This shift empowers individuals to handle their own health more actively and reduces the need for frequent clinical visits, supporting the nation’s broader movement toward value-driven care and digital transformation.
Major companies participating in the U.S. Remote Patient Monitoring Market include Abbott Laboratories, Baxter International, BIOTRONIK SE & Co. KG, Boston Scientific, Dexcom, F. Hoffmann-La Roche Ltd, GE Healthcare, Johnson & Johnson, Koninklijke Philips N.V., Medtronic, OMRON, Sotera Wireless, and VitalConnect. Key strategies adopted by leading companies in the U.S. Remote Patient Monitoring Market are centered around strengthening product integration, enhancing data accuracy, and expanding their connected-care ecosystems. Many organizations are investing in advanced biosensor innovation, improving device interoperability, and developing software platforms that support real-time clinical decision-making. Firms are also entering collaborations with healthcare providers to boost adoption across chronic-care programs and expanding cloud-based analytics to improve predictive capabilities. Continuous upgrades in user-friendly interfaces, secure data-sharing channels, and scalable monitoring solutions help broaden their reach across home-care settings.
This product will be delivered within 2-4 business days.
The steady rise is linked to several influential factors, including the growing rate of long-term health conditions across the country and expanding reimbursement frameworks that encourage digital care adoption. RPM technologies allow individuals to measure essential health indicators such as blood glucose levels, heart rate, and blood pressure from their homes, supporting earlier intervention and minimizing unnecessary hospital visits. As chronic disease cases continue to climb, these platforms are becoming an essential component of modern care models, particularly for long-term disease control and preventive healthcare. The RPM landscape covers a wide spectrum of medical tools designed to capture and transfer patient information outside clinical facilities. It incorporates digital systems that evaluate incoming data and support ongoing communication between patients and healthcare professionals. In addition, the market includes specialized devices engineered by manufacturers to integrate efficiently with dedicated RPM platforms, improving data synchronization and overall care delivery.
The cardiac monitoring devices segment held a 19.6% share in 2024. Its expansion is attributed to the substantial burden of cardiovascular conditions nationwide and a rising need for continuous, real-time cardiac oversight that enables quicker diagnosis and more effective treatment. Advancements in cardiac-focused RPM technologies have elevated accuracy through refined sensors and intelligent analytics capable of assessing heart rhythm patterns, variability, and additional vital indicators with precision.
The diabetes segment accounted for a 56.4% share in 2024, supported by the increasing number of individuals managing diabetes and the growing demand for consistent, real-time metabolic monitoring. While the condition remains most common among adults above 45, diagnoses among younger groups are becoming more frequent, increasing the need for reliable digital tools that simplify ongoing disease management. RPM solutions play a meaningful role in monitoring blood glucose and other metabolic markers and have significantly improved the way diabetes is managed through enhanced technical capabilities.
The home-care settings segment held 69.8% share in 2024, driven by rising interest in decentralized care models and a preference for managing personal health from familiar surroundings. This shift empowers individuals to handle their own health more actively and reduces the need for frequent clinical visits, supporting the nation’s broader movement toward value-driven care and digital transformation.
Major companies participating in the U.S. Remote Patient Monitoring Market include Abbott Laboratories, Baxter International, BIOTRONIK SE & Co. KG, Boston Scientific, Dexcom, F. Hoffmann-La Roche Ltd, GE Healthcare, Johnson & Johnson, Koninklijke Philips N.V., Medtronic, OMRON, Sotera Wireless, and VitalConnect. Key strategies adopted by leading companies in the U.S. Remote Patient Monitoring Market are centered around strengthening product integration, enhancing data accuracy, and expanding their connected-care ecosystems. Many organizations are investing in advanced biosensor innovation, improving device interoperability, and developing software platforms that support real-time clinical decision-making. Firms are also entering collaborations with healthcare providers to boost adoption across chronic-care programs and expanding cloud-based analytics to improve predictive capabilities. Continuous upgrades in user-friendly interfaces, secure data-sharing channels, and scalable monitoring solutions help broaden their reach across home-care settings.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The companies profiled in this U.S. Remote Patient Monitoring market report include:- Abbott Laboratories
- Baxter International
- BIOTRONIK SE & Co. KG
- Boston Scientific
- Dexcom
- F. Hoffmann-La Roche Ltd
- GE Healthcare
- Johnson & Johnson
- Koninklijke Philips N.V.
- Medtronic
- OMRON
- Sotera Wireless
- VitalConnect
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 60 |
| Published | December 2025 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value ( USD | $ 9.4 Billion |
| Forecasted Market Value ( USD | $ 25.2 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | United States |
| No. of Companies Mentioned | 14 |
